Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 24INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

fludarabine phosphate 1fludarabine 1daratumumab 1carfilzomib 1Lenalidomide 1Dexamethasone 1Cyclophosphamide 1Azacitidine 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Neoplasms, Plasma Cell × fludarabine × Clear all
NCT05528887 2022-09-06

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The Affiliated People's Hospital of Ningbo University

Phase 1 Recruiting
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡